[ARNA] Arena Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 396.16 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 1.53 Change: 0.06 (4.08%)
Ext. hours: Change: 0 (0%)

chart ARNA

Refresh chart

Strongest Trends Summary For ARNA

ARNA is in the long-term up 196% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. Its products under development include APD811, an agonist of the prostacyclin receptor, which has completed single- and multiple-ascending dose Phase I trials for the treatment of pulmonary arterial hypertension; and temanogrel, an inverse agonist of the serotonin 2A receptor for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I trials. The company?s products under development also comprise APD334, an agonist of the sphingosine 1-phosphate subtype 1 receptor for the treatment of conditions related to autoimmune diseases, which has completed Phase I single-ascending dose trial; and APD371, an agonist of the cannabinoid receptor 2 that is in Phase I single-ascending dose trial for the treatment of pain. It also manufactures drug

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding243.04 M EPS0.02 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -4.26% Sales Growth - Q/Q33.35% P/E65.5
P/E To EPS Growth P/S9.34 P/BV3.07 Price/Cash Per Share
Price/Free Cash Flow-3.59 ROA-16.44% ROE-46.18% ROI
Current Ratio3.61 Quick Ratio3.46 Long Term Debt/Equity0.35 Debt Ratio0.58
Gross Margin76.36% Operating Margin-243.99% Net Profit Margin-140.4% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities101.41 M Cash From Investing Activities-1.07 M Cash From Operating Activities-23.02 M Gross Profit8.66 M
Net Profit-24.3 M Operating Profit-21.74 M Total Assets362.29 M Total Current Assets268.62 M
Total Current Liabilities74.36 M Total Debt70.17 M Total Liabilities233.35 M Total Revenue12.26 M
Technical Data
High 52 week49.63 Low 52 week30.89 Last close43.58 Last change-0.37%
RSI72.62 Average true range2.02 Beta1.02 Volume2.08 M
Simple moving average 20 days7.91% Simple moving average 50 days9.66% Simple moving average 200 days6.16%
Performance Data
Performance Week-0.91% Performance Month6.06% Performance Quart10.83% Performance Half-2.22%
Performance Year28.63% Performance Year-to-date11.89% Volatility daily3.16% Volatility weekly7.07%
Volatility monthly14.48% Volatility yearly50.18% Relative Volume420.94% Average Volume624.51 K
New High New Low


2019-06-14 18:29:41 | Did Hedge Funds Drop The Ball On Arena Pharmaceuticals, Inc. ARNA

2019-06-13 08:30:00 | Arena Pharmaceuticals to Present at JMP Securities Life Sciences Conference on June 19

2019-06-07 09:30:01 | Why Is Arena Pharmaceuticals ARNA Up 9.1% Since Last Earnings Report?

2019-06-06 12:32:35 | Does Market Volatility Impact Arena Pharmaceuticals, Inc.'s NASDAQ:ARNA Share Price?

2019-05-21 07:30:00 | Corvidia Therapeutics Announces Dr. Preston Klassen Joins its Board of Directors

2019-05-17 08:30:00 | Arena Pharmaceuticals' Presence at Digestive Disease Week DDW Reinforces Commitment to the Gastrointestinal Disease Community

2019-05-13 11:35:18 | Cannabis Sector Weekly Update: Sell-Off amid Market Weakness

2019-05-13 09:00:01 | All You Need to Know About Arena Pharmaceuticals ARNA Rating Upgrade to Buy

2019-05-13 08:30:00 | Arena Pharmaceuticals to Participate in Upcoming Investor Conferences

2019-05-10 19:45:04 | Arena Pharmaceuticals Inc ARNA Q1 2019 Earnings Call Transcript

2019-05-10 07:04:25 | Did Business Growth Power Arena Pharmaceuticals's NASDAQ:ARNA Share Price Gain of 226%?

2019-05-09 16:24:00 | S&P 500, Nasdaq end lower for fourth day after Trump claims China ‘broke the deal’

2019-05-09 16:18:50 | Edited Transcript of ARNA earnings conference call or presentation 8-May-19 8:30pm GMT

2019-05-09 09:03:01 | Arena Pharmaceuticals' ARNA Loss Widens in Q1 But Stock Up

2019-05-08 16:46:00 | Arena Pharmaceutical shares slide after drug maker reports disappointing financial results

2019-05-08 16:01:00 | Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2019 Financial Results

2019-05-07 13:20:02 | Key Cannabis Sector Updates: Analyst Ratings and Earnings

2019-05-07 11:45:50 | Cannabis Stocks Had a Mixed Performance Last Week

2019-05-02 09:26:01 | United Therapeutics UTHR Down Despite Q1 Earnings Beat

2019-05-01 08:30:00 | Arena Pharmaceuticals to Release First Quarter 2019 Financial Results and Provide Corporate Update on May 8

2019-04-30 14:50:37 | Here’s What Hedge Funds Think About Arena Pharmaceuticals, Inc. ARNA

2019-04-29 12:05:22 | Ups and Downs in the Cannabis Space Last Week

2019-04-24 11:30:21 | The New Cannabis ETF Is Already Making Additions

2019-04-22 15:15:02 | Wall Street Ratings for Cannabis Stocks Last Week

2019-04-03 11:52:59 | What Type Of Shareholder Owns Arena Pharmaceuticals, Inc.'s NASDAQ:ARNA?

2019-04-03 08:30:00 | Arena Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 10

2019-04-02 09:35:25 | Analysts Love Charlotte’s Web Holdings despite Q4 Earnings Miss

2019-03-29 09:40:13 | Charlotte’s Web Holdings Reports Record Harvest in 2018

2019-03-28 09:30:01 | Why Is Arena Pharmaceuticals ARNA Down 10.1% Since Last Earnings Report?

2019-03-26 08:05:05 | Charlotte’s Web Holdings Is Outperforming Peers in March

2019-03-26 07:30:00 | New Research Coverage Highlights The Blackstone Group, Arena Pharmaceuticals, Arrow Electronics, AdvanSix, KBR, and RPM International — Consolidated Revenues, Company Growth, and Expectations for 2019

2019-03-18 15:36:06 | These 3 Cannabis Stocks Are Set to Skyrocket, Say Analysts

2019-03-08 08:30:00 | Arena Pharmaceuticals Presented New Phase 2 Data for Etrasimod and Olorinab at the 14th Congress of European Crohn's and Colitis Organisation

2019-02-28 10:16:03 | United Therapeutics UTHR Q4 Earnings & Sales Beat Estimates

2019-02-27 16:09:45 | Edited Transcript of ARNA earnings conference call or presentation 26-Feb-19 9:30pm GMT

2019-02-27 08:25:01 | Arena Pharmaceuticals ARNA Beats on Q4 Earnings & Revenues

2019-02-26 20:52:36 | Arena Pharmaceuticals Inc ARNA Q4 2018 Earnings Conference Call Transcript

2019-02-26 16:01:00 | Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results

2019-02-25 15:25:04 | 5 Clinical Stage Biotech Stocks to Buy

2019-02-21 08:30:00 | Arena Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference on February 27

2019-02-20 16:01:00 | Arena Pharmaceuticals to Announce Fourth Quarter and Full-Year 2018 Financial Results and Provide Corporate Update on February 26

2019-02-15 09:05:51 | Top 3 Marijuana Stocks on the NASDAQ

2019-02-07 16:30:00 | Arena Pharmaceuticals Presents Preclinical and Early Clinical Development Data for Olorinab at Crohn's & Colitis Congress

2019-01-30 10:23:41 | Is Arena Pharmaceuticals, Inc. NASDAQ:ARNA A Financially Strong Company?

2019-01-30 07:55:00 | Research Report Identifies Cameco, American Equity Investment Life Holding, AG Mortgage Investment Trust, Arena Pharmaceuticals, Mimecast, and Aldeyra Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2019-01-25 07:38:05 | The Daily Biotech Pulse: Intuitive Surgical Earnings, Corbus To Offer Shares, Eton In-Licenses Neurologic Drug

2019-01-24 20:00:00 | United Therapeutics Announces Closing Of License Agreement With Arena Pharmaceuticals For Ralinepag

2019-01-24 20:00:00 | Arena Pharmaceuticals Announces Closing of Global License Agreement with United Therapeutics for Ralinepag

2019-01-21 10:53:42 | Top Marijuana Stocks on the NASDAQ

2019-01-07 08:30:00 | Arena Pharmaceuticals Reports Positive Long-Term Data from the Open-Label Extension of the Phase 2 OASIS Trial Evaluating Etrasimod for Treatment of Ulcerative Colitis